Skip to content

Change in AR at other companies

ALN
Alnylam PharmaceuticalsALNY
$110.42M+1,385%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$0+100%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$690K-143%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$25.53M-1,333%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$7.16M-87.6%
Incyte logo
IncyteINCY
$27.03M+187%

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.17B+106%

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's change in AR?
Intellia Therapeutics (NTLA) reported change in AR of -$337K in Q1 2026.
How has Intellia Therapeutics's change in AR changed year-over-year?
Intellia Therapeutics's change in AR decreased by 117.0% year-over-year, from $1.99M to -$337K.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.